Research progress in the liquid biopsy in hepatocellular carcinoma

Abstract

Abstract: At present, primary hepatocellular carcinoma ranks fourth common malignant tumor and second tumor cause of death in China, seriously threatening the pubic life and health.Because of its hidden incidence and non-specific clinical manifestations, the early diagnosis rate of primary liver cancer is low.When liver cancer is found,the condition often have progressed to the advanced stage and the prognosis is very poor.Therefore, modern medicine there is an urgent need for new detection methods to early diagnosis, real-time monitoring and effective treatment of liver cancer."Liquid biopsy" is one of the new detection methods.Many studies have shown that liquid biopsy is of great significance in the early diagnosis, targeted treatment, metastasis, recurrence and prognostic evaluation of liver cancer. The purpose of this review is to briefly introduce the research progress of liquid biopsy in hepatocellular carcinoma.

Key words: Primary hepatocellular carcinoma, Liquid biopsy, Circulating tumor cells, Exosomes, Platelet

Liang Renshan, Zhang Yu, Chen Zutao, Feng Tingting. Research progress in the liquid biopsy in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(1): 30-33.

References

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等. 原发性肝癌的分层筛查与监测指南(2020版)[J/CD]. 肝癌电子杂志,2021,8(1):1-15.
[3] 曾红梅,蔡建强. 中国肝癌诊治现状再思考[J/OL]. 肝癌电子杂志,2021,8(2):23-25.
[4] YE Q, LING S, ZHENG S, et al.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114.
[5] VON FELDEN J, GARCIA-LEZANA T, SCHULZE K, et al.Liquid biopsy in the clinical management of hepatocellular carcinoma[J]. Gut, 2020, 69(11): 2025-2034.
[6] WAN J C M, MASSIE C, GARCIA-CORBACHO J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238.
[7] CAI J, CHEN L, ZHANG Z, et al.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12): 2195-2205.
[8] CROWLEY E, DI NICOLANTONIO F, LOUPAKIS F, et al.Liquid biopsy: monitoring cancer-genetics in the blood[J]. Nat Rev Clin Oncol, 2013, 10(8): 472-484.
[9] ASHWORTH T R.A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Australia Med J, 1969, 14: 146-147.
[10] VAN DE STOLPE A, PANTEL K, SLEIJFER S, et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use[J]. Cancer Res, 2011, 71(18): 5955-5960.
[11] OGLE L F, ORR J G, WILLOUGHBY C E, et al.Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?[J]. J Hepatol, 2016, 65(2): 305-313.
[12] ESPEJO-CRUZ M L, GONZáLEZ-RUBIO S, ESPEJO J J, et al. Enumeration and characterization of circulating tumor cells in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Int J Mol Sci, 2023, 24(3): 2558.
[13] MENG S D, TRIPATHY D, FRENKEL E P, et al.Circulating tumor cells in patients with breast cancer dormancy[J]. Clin Cancer Res, 2004, 10(24): 8152-8162.
[14] KUSTANOVICH A, SCHWARTZ R, PERETZ T, et al.Life and death of circulating cell-free DNA[J]. 2019, 20(8): 1057-1067.
[15] VAN DER VAART M, PRETORIUS P J. The origin of circulating free DNA[J]. Clin Chemi, 2007, 53(12): 2215.
[16] STROUN M, LYAUTEY J, LEDERREY C, et al.About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release[J]. Clin Chim Acta, 2001, 313(1-2): 139-142.
[17] ANKER P, STROUN M, MAURICE P A.Spontaneous release of dna by human-blood lymphocytes as shown in an invitro system[J]. Cancer Res, 1975, 35(9): 2375-2382.
[18] HAO X, LUO H, KRAWCZYK M, et al.DNA methylation markers for diagnosis and prognosis of common cancers[J]. Proc Natl Acad Sci U S A, 2017, 114(28): 7414-7419.
[19] XU R H, WEI W, KRAWCZYK M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161.
[20] NGUYEN V C, NGUYEN T H, PHAN T H, et al.Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma[J]. BMC Cancer, 2023, 23(1): 233.
[21] EL ANDALOUSSI S, MäGER I, BREAKEFIELD X O, et al. Extracellular vesicles: biology and emerging therapeutic opportunities[J]. Nat Rev Drug Discov, 2013, 12(5): 347-357.
[22] CHEN R, XU X, TAO Y, et al.Exosomes in hepatocellular carcinoma: a new horizon[J]. Cell Commun Signal, 2019, 17(1): 1.
[23] GUO W, GAO Y, LI N, et al.Exosomes: new players in cancer[J]. Oncol Rep, 2017, 38(2): 665-675.
[24] SUN F, WANG J-Z, LUO J-J, et al.Exosomes in the oncobiology, diagnosis, and therapy of hepatic carcinoma: a new player of an old game[J]. Biom Res Int, 2018, 2018: 2747461.
[25] HOU P P, LUO L J, CHEN H Z, et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment[J]. Mol Cell, 2020, 78(6): 1192-1206.e10.
[26] HOSHINO A, COSTA-SILVA B, SHEN T-L, et al.Tumour exosome integrins determine organotropic metastasis[J]. Nature, 2015, 527(7578): 329-335.
[27] MOUSAVI S M, AMIN MAHDIAN S M, EBRAHIMI M S, et al. Microfluidics for detection of exosomes and microRNAs in cancer: State of the art[J]. Mol Ther Nucleic Acids, 2022, 28: 758-791.
[28] LI X, MA Y, LIU C, et al.Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells[J]. Transfusion, 2023, 63(10): 1821-1831.
[29] LEVIN J, CONLEY C L.THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE[J]. Archives of internal medicine, 1964, 114: 497-500.
[30] GASIC G J, GASIC T B, STEWART C C.Antimetastatic effects associated with platelet reduction[J]. Proc Natl Acad Sci U S A, 1968, 61(1): 46-52.
[31] GASIC G J, GASIC T B, GALANTI N, et al.Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease[J]. Int J Cancer, 1973, 11(3): 704-718.
[32] MA J Y, KE L C, LIU Q.The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer: a Meta-analysis[J]. Medicine (Baltimore), 2018, 97(43):e12897
[33] ZHANG L X, WEI Z J, XU A M, et al.Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study[J]. Int J Surg, 2018, 56: 320-327.
[34] TEMUR I, GULEC U K, PAYDAS S, et al.Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer[J]. Eur J Obstet Gynecol Reprod Biol 2018, 226: 25-29.
[35] BEST M G, WURDINGER T.Tumor-educated platelets for the earlier detection of hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2020, 44(6): 794-795.
[36] JIANG X, WONG K H K, KHANKHEL A H, et al. Microfluidic isolation of platelet-covered circulating tumor cells[J]. Lab Chip, 2017, 17(20): 3498-3503.
[37] IN 'T VELD S G J G, WURDINGER T. Tumor-educated platelets[J]. Blood, 2019, 133(22): 2359-2364.
[38] BEST M G, SOL N, KOOI I, et al.RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics[J]. Cancer Cell, 2015, 28(5): 666-676.
[39] ASGHAR S, WAQAR W, UMAR M, et al.Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: Liquid biopsy an alternative approach to tissue biopsy[J]. Clin Res Hepatol Gastroenterol, 2020, 44(6): 836-844.
[40] HEITZER E, HAQUE I S, ROBERTS C E S, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2019, 20(2): 71-88.